TY - T1的口服抗凝治疗应盘ontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02323-2019 VL - 55 IS - 1 SP - 1902323 AU - Meyer, Guy AU - Konstantinides, Stavros Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/55/1/1902323.abstract N2 - We would like to thank H. Slabbynck and co-workers for their interest in the 2019 European Society of Cardiology/European Respiratory Society guidelines on the diagnosis and management of acute pulmonary embolism (PE), and for their interesting comment on the treatment duration of patients with a high-risk PE secondary to a major transient/reversible risk factor.For patients with first pulmonary embolism secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months http://bit.ly/2Pp68Ti ER -